

1305. Eur Arch Otorhinolaryngol. 2018 Jan;275(1):225-232. doi:
10.1007/s00405-017-4806-2. Epub 2017 Nov 25.

Prognostic value of CD45 transcriptional expression in head and neck cancer.

Camacho M(1), Agüero A(2), Sumarroca A(2), López L(3), Pavón MÁ(4)(5),
Avilés-Jurado FX(6), García J(2), Quer M(2), León X(7)(8).

Author information: 
(1)Laboratory of Angiology, Vascular Biology and Inflammation, Institute of
Biomedical Research (IIB Sant Pau), Barcelona, Spain.
(2)Otorhinolaryngology Department, Hospital de la Santa Creu i Sant Pau,
Universitat Autònoma de Barcelona, C/Mas Casanovas, 90, 08041, Barcelona, Spain.
(3)Pathology Department, Hospital de la Santa Creu i Sant Pau, Universitat
Autònoma de Barcelona, Barcelona, Spain.
(4)Infections and Cancer Laboratory, Cancer Epidemiology Research Program,
Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
(5)Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y
Nanomedicina (CIBER-BBN), Madrid, Spain.
(6)Otorhinolaryngology Department, Hospital Clínic, Barcelona, Spain.
(7)Otorhinolaryngology Department, Hospital de la Santa Creu i Sant Pau,
Universitat Autònoma de Barcelona, C/Mas Casanovas, 90, 08041, Barcelona, Spain. 
xleon@santpau.cat.
(8)Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y
Nanomedicina (CIBER-BBN), Madrid, Spain. xleon@santpau.cat.

INTRODUCTION: Tumor-infiltrating lymphocytes (TILs) have a recognized antitumor
activity in head and neck squamous cell carcinoma (HNSCC). CD45 is one of the
most highly expressed proteins in lymphocytes. We carry out a study to assess the
prognostic value of transcriptional expression of CD45 in HNSCC.
MATERIAL AND METHODS: We determined the transcriptional expression of CD45 in 160
consecutive HNSCC patients and compared the TIL values according to the CD45
expression.
RESULTS: Five-year disease-free survival for patients with a high transcriptional
expression of CD45 (n = 107) was 62.4% and for patients with a low expression
(n = 53) it was 36.2% (P = 0.003). Patients with a high expression of CD45 had a 
better local recurrence-free survival and disease-specific survival. The results 
of a multivariate analysis showed that patients with a low expression of CD45 had
2.0-fold high risk of recurrence (95% CI 1.2-3.2, P = 0.003). In oropharyngeal
carcinomas, HPV-positive tumors showed a higher transcriptional CD45 expression
than HPV-negative tumors. Tumors with high CD45 expression had
immunohistochemical TIL scores significantly higher than those with low CD45
expression.
CONCLUSION: According to our results, CD45 expression is a potential marker for
tumor outcome in HNSCC patients.

DOI: 10.1007/s00405-017-4806-2 
PMID: 29177949  [Indexed for MEDLINE]
